AveXis, Inc. (NASDAQ:AVXS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

According to Zacks, “AveXis, Inc. is a gene therapy company which develops and commercializes treatments for neurological genetic diseases primarily in United States. The Company’s product candidate consists of AVXS-101 which is in clinical trial for the treatment of spinal muscular atrophy Type 1, the genetic cause of infant mortality. AveXis, Inc. is headquartered in Bannockburn, Illinois. “

A number of other analysts also recently weighed in on AVXS. Jefferies Group LLC reissued a “buy” rating and set a $108.00 price target (up previously from $92.00) on shares of AveXis in a research report on Friday, August 11th. BMO Capital Markets reissued a “buy” rating and set a $123.00 price target on shares of AveXis in a research report on Friday, August 11th. Morgan Stanley reissued an “overweight” rating and set a $118.00 price target on shares of AveXis in a research report on Wednesday, August 9th. Wells Fargo & Company reissued an “outperform” rating and set a $134.00 price target (up previously from $89.00) on shares of AveXis in a research report on Tuesday. Finally, Chardan Capital set a $103.00 price target on shares of AveXis and gave the stock a “buy” rating in a research report on Sunday, June 18th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and thirteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $99.75.

Shares of AveXis (NASDAQ:AVXS) traded up 0.77% on Thursday, reaching $93.30. 261,855 shares of the company were exchanged. The stock’s market capitalization is $2.98 billion. AveXis has a 1-year low of $32.31 and a 1-year high of $99.45. The company has a 50-day moving average price of $92.16 and a 200 day moving average price of $78.67.

AveXis (NASDAQ:AVXS) last released its quarterly earnings results on Thursday, August 10th. The company reported ($2.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by $1.10. During the same period last year, the business earned ($0.68) EPS. On average, analysts forecast that AveXis will post ($5.94) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “AveXis, Inc. (AVXS) Lifted to Hold at Zacks Investment Research” was first published by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/07/avexis-inc-avxs-lifted-to-hold-at-zacks-investment-research.html.

In other AveXis news, VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $93.25, for a total value of $165,985.00. Following the sale, the vice president now directly owns 1,780 shares in the company, valued at $165,985. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 5,340 shares of company stock worth $474,637 over the last quarter. 18.60% of the stock is currently owned by company insiders.

Hedge funds have recently bought and sold shares of the business. Lord Abbett & CO. LLC bought a new stake in shares of AveXis during the second quarter valued at about $20,614,000. Ameritas Investment Partners Inc. raised its stake in shares of AveXis by 331.0% during the second quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock valued at $174,000 after purchasing an additional 1,622 shares in the last quarter. California State Teachers Retirement System raised its stake in shares of AveXis by 280.6% during the second quarter. California State Teachers Retirement System now owns 43,538 shares of the company’s stock valued at $3,577,000 after purchasing an additional 32,100 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of AveXis by 210.9% during the second quarter. The Manufacturers Life Insurance Company now owns 15,961 shares of the company’s stock valued at $1,312,000 after purchasing an additional 10,827 shares in the last quarter. Finally, PointState Capital LP raised its stake in shares of AveXis by 118.7% during the second quarter. PointState Capital LP now owns 544,667 shares of the company’s stock valued at $44,750,000 after purchasing an additional 295,600 shares in the last quarter. Institutional investors own 94.71% of the company’s stock.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Get a free copy of the Zacks research report on AveXis (AVXS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.